Monte Rosa Therapeutics (GLUE) Operating Income (2023 - 2025)
Historic Operating Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$33.0 million.
- Monte Rosa Therapeutics' Operating Income fell 2430.73% to -$33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 10659.87%. This contributed to the annual value of -$81.1 million for FY2024, which is 4340.14% up from last year.
- Per Monte Rosa Therapeutics' latest filing, its Operating Income stood at -$33.0 million for Q3 2025, which was down 2430.73% from -$15.6 million recorded in Q2 2025.
- Monte Rosa Therapeutics' Operating Income's 5-year high stood at $44.0 million during Q1 2025, with a 5-year trough of -$37.2 million in Q2 2023.
- For the 3-year period, Monte Rosa Therapeutics' Operating Income averaged around -$20.8 million, with its median value being -$33.0 million (2025).
- Data for Monte Rosa Therapeutics' Operating Income shows a peak YoY increase of 22600.8% (in 2025) and a maximum YoY decrease of 2430.73% (in 2025) over the last 5 years.
- Over the past 3 years, Monte Rosa Therapeutics' Operating Income (Quarter) stood at -$34.9 million in 2023, then skyrocketed by 137.3% to $13.0 million in 2024, then plummeted by 353.58% to -$33.0 million in 2025.
- Its Operating Income was -$33.0 million in Q3 2025, compared to -$15.6 million in Q2 2025 and $44.0 million in Q1 2025.